RPL31P59

Across TCGA pan-cancer cohorts, RPL31P59 RNA is linked to patient survival in 10 of 34 cancer types, making it the most broadly survival-associated RPL31P59 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RPL31P59 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RPL31P59 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LAML show a favorable association.

LIHC, HNSC, and KIRC are the cancer types where RPL31P59 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.412	0.790	<.001	126	view →
HNSC	DFS	Tertile	IV	0.717	0.298	.013	75	view →
KIRC	DFS	Tertile	III,IV	0.528	0.757	.026	42	view →
COAD	OS	Tertile	III,IV	0.175	0.708	<.001	36	view →
KIRP	OS	Tertile	All	0.826	0.951	.002	24	view →
LAML	DFS	Tertile	All	0.663	0.352	.004	18	view →
LUAD	OS	Tertile	All	0.579	0.695	.034	9	view →
GBM	DFS	Tertile	All	0.126	0.305	.020	9	view →
THCA	OS	Tertile	All	0.555	0.963	.004	9	view →
STAD	OS	Median	III,IV	0.333	0.635	.018	8	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

RPL31P59–LIHC (OS)

Open the LIHC breakdown →